Expanded Access for Apixaban
- Registration Number
- NCT05187286
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This is an expanded access designed to provide access to apixaban for eligible participants.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention
- Previously participated in the CV185-362 study and was on apixaban for 1 year or until treatment was no longer required
Exclusion Criteria
- Weight less than 5 kg or greater than 35 kg
Other inclusion/exclusion criteria apply
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Childrens Hospital Of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States